Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ROBERT JAMES HOPKIN

Allopathic & Osteopathic Physicians Medical Genetics Clinical Genetics (M.D.)

NPI
1447281878
CMS profile
246841
Location
CINCINNATI, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$114,110.74

59 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
GENZYME CORPORATION $60,705.25 35
Amicus Therapeutics, Inc. $36,155.16 17
Chiesi USA, Inc. $17,207.47 6
SANOFI-AVENTIS U.S. LLC $42.86 1

Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ROBERT JAMES HOPKIN

NPI 1447281878 · CMS profile ID 246841

Allopathic & Osteopathic Physicians / Medical Genetics / Clinical Genetics (M.D.)

CINCINNATI, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1447281878?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ROBERT JAMES HOPKIN, NPI 1447281878, CMS profile ID 246841. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1447281878?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). ROBERT JAMES HOPKIN, NPI 1447281878, CMS profile ID 246841. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1447281878?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
ROBERT JAMES HOPKIN, NPI 1447281878, CMS profile ID 246841, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1447281878?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

59 matching records · $114,110.74 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 59 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–59 of 59.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amicus Therapeutics, Inc. $741.4002/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148420633 CMS
Amicus Therapeutics, Inc. $1,685.1502/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148420825 CMS
Amicus Therapeutics, Inc. $675.0002/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148420885 CMS
Amicus Therapeutics, Inc. $177.5002/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148420931 CMS
GENZYME CORPORATION $44.1902/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139645636 CMS
GENZYME CORPORATION $100.2402/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139645638 CMS
Amicus Therapeutics, Inc. $123.5502/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148420823 CMS
Amicus Therapeutics, Inc. $2,245.0001/25/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148420553 CMS
Amicus Therapeutics, Inc. $2,245.0001/16/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148420695 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $56,411.70 53
PY2020 $30,339.32 16
PY2021 $29,299.23 17
PY2022 $28,503.21 21
PY2023 $91,514.52 47
PY2024 $114,110.74 59
PY2025 $68,896.85 44

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,153,481.74 135
PY2024 Principal investigator $224,332.16 27
PY2023 Recipient $1,250.00 1
PY2023 Principal investigator $345,768.63 73
PY2022 Recipient $750.00 2
PY2022 Principal investigator $119,811.98 7
PY2021 Principal investigator $325,671.58 142
PY2020 Recipient $1,972.21 4
PY2020 Principal investigator $177,074.66 44
PY2019 Recipient $1,983.14 7
PY2019 Principal investigator $92,328.62 22

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

135 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Amicus Therapeutics, Inc. $9,509.23 12/22/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With LOPD No dispute reported 06/30/2026 1252320269
Principal investigator 1 GENZYME CORPORATION $66,004.00 12/22/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
An Open-label, Multinational, Multicenter, Intravenous Infusion Study of the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Avalglucosidase Alfa in Treatment naive Pediatric Participants With Infantile-Onset Pompe Disease (IOPD) No dispute reported 06/30/2026 1226123490
Principal investigator 1 GENZYME CORPORATION $25,414.00 12/08/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
An Open-label, Multinational, Multicenter, Intravenous Infusion Study of the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Avalglucosidase Alfa in Treatment naive Pediatric Participants With Infantile-Onset Pompe Disease (IOPD) No dispute reported 06/30/2026 1226123482
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,780.00 12/01/2025 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
GAUCHER DISEASE OUTCOME SURVEY (GOS) AN OBSERVATIONAL, INTERNATIONAL, MULTICENTER, LONG-TERM REGISTRY OF PATIENTS WITH GAUCHER DISEASE No dispute reported 06/30/2026 1223264886
Principal investigator 1 Amicus Therapeutics, Inc. $4,896.59 11/14/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With LOPD No dispute reported 06/30/2026 1252319929
Principal investigator 1 Amicus Therapeutics, Inc. $62,186.16 11/07/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With LOPD No dispute reported 06/30/2026 1252319927
Principal investigator 1 SANOFI US SERVICES INC. $2,092.50 11/07/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Gaucher Disease Registry Protocol No dispute reported 06/30/2026 1226119084
Principal investigator 1 SANOFI US SERVICES INC. $45,933.75 11/05/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Fabry Disease Registry Protocol No dispute reported 06/30/2026 1226119092
Principal investigator 1 GENZYME CORPORATION $24,597.00 11/04/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
An Open-label, Multinational, Multicenter, Intravenous Infusion Study of the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Avalglucosidase Alfa in Treatment naive Pediatric Participants With Infantile-Onset Pompe Disease (IOPD) No dispute reported 06/30/2026 1226123478
Principal investigator 1 GENZYME CORPORATION $6,361.00 10/24/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
A Randomized, Double-blind, Placebo-controlled, 12-month Phase 3 Study to Evaluate the Effect of Venglustat on Neuropathic and Abdominal Pain in Male and Female Adults With Fabry Disease Who Are Treatment-naive or Untreated for at Least 6 Months No dispute reported 06/30/2026 1226130103
Principal investigator 1 Amicus Therapeutics, Inc. $67,787.91 10/22/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With LOPD No dispute reported 06/30/2026 1252319925
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $17,010.00 10/02/2025 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
GAUCHER DISEASE OUTCOME SURVEY (GOS) AN OBSERVATIONAL, INTERNATIONAL, MULTICENTER, LONG-TERM REGISTRY OF PATIENTS WITH GAUCHER DISEASE No dispute reported 06/30/2026 1223264882
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,000.00 10/02/2025 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
GAUCHER DISEASE OUTCOME SURVEY (GOS) AN OBSERVATIONAL, INTERNATIONAL, MULTICENTER, LONG-TERM REGISTRY OF PATIENTS WITH GAUCHER DISEASE No dispute reported 06/30/2026 1223264884
Principal investigator 1 GENZYME CORPORATION $66,679.00 09/15/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
An Open-label, Multinational, Multicenter, Intravenous Infusion Study of the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Avalglucosidase Alfa in Treatment naive Pediatric Participants With Infantile-Onset Pompe Disease (IOPD) No dispute reported 06/30/2026 1226123444
Principal investigator 1 GENZYME CORPORATION $12,065.00 09/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
An Open-label, Multinational, Multicenter, Intravenous Infusion Study of the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Avalglucosidase Alfa in Treatment naive Pediatric Participants With Infantile-Onset Pompe Disease (IOPD) No dispute reported 06/30/2026 1226123455
Principal investigator 1 Amicus Therapeutics, Inc. $2,000.00 08/06/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/​Miglustat in IOPD Subjects Aged 0 to <18 (ROSSELLA) No dispute reported 06/30/2026 1252320547
Principal investigator 1 SANOFI US SERVICES INC. $12,791.25 07/30/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Fabry Disease Registry Protocol No dispute reported 06/30/2026 1226119058
Principal investigator 1 SANOFI US SERVICES INC. $14,512.50 07/23/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Gaucher Disease Registry Protocol No dispute reported 06/30/2026 1226119055
Principal investigator 1 GENZYME CORPORATION $24,934.00 07/21/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
An Open-label, Multinational, Multicenter, Intravenous Infusion Study of the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Avalglucosidase Alfa in Treatment naive Pediatric Participants With Infantile-Onset Pompe Disease (IOPD) No dispute reported 06/30/2026 1226123421
Principal investigator 1 GENZYME CORPORATION $4,930.00 07/11/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
A Randomized, Double-blind, Placebo-controlled, 12-month Phase 3 Study to Evaluate the Effect of Venglustat on Neuropathic and Abdominal Pain in Male and Female Adults With Fabry Disease Who Are Treatment-naive or Untreated for at Least 6 Months No dispute reported 06/30/2026 1226130098
Principal investigator 1 Amicus Therapeutics, Inc. $3,500.00 07/09/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With LOPD No dispute reported 06/30/2026 1252319923
Principal investigator 1 GENZYME CORPORATION $81,875.00 07/07/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
An Open-label, Multinational, Multicenter, Intravenous Infusion Study of the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Avalglucosidase Alfa in Treatment naive Pediatric Participants With Infantile-Onset Pompe Disease (IOPD) No dispute reported 06/30/2026 1226123416
Principal investigator 1 GENZYME CORPORATION $16,400.00 07/02/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
A Prospective Observational Study to Describe Clinical Outcomes of Alglucosidase Alfa Treatment in Patients =6 Months of Age With Infantile-onset Pompe Disease (IOPD) No dispute reported 06/30/2026 1226125922
Principal investigator 1 Amicus Therapeutics, Inc. $178,945.86 06/18/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With LOPD No dispute reported 06/30/2026 1252320541
Principal investigator 1 GENZYME CORPORATION $2,000.00 06/09/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
A Prospective Observational Study to Describe Clinical Outcomes of Alglucosidase Alfa Treatment in Patients =6 Months of Age With Infantile-onset Pompe Disease (IOPD) No dispute reported 06/30/2026 1226125919
Principal investigator 1 Amicus Therapeutics, Inc. $23,620.00 06/06/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With LOPD No dispute reported 06/30/2026 1252320543
Principal investigator 1 Amicus Therapeutics, Inc. $39,700.00 06/05/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With LOPD No dispute reported 06/30/2026 1252319921
Principal investigator 1 Amicus Therapeutics, Inc. $24,250.00 05/21/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/​Miglustat in IOPD Subjects Aged 0 to <18 (ROSSELLA) No dispute reported 06/30/2026 1252320053
Principal investigator 1 Amicus Therapeutics, Inc. $3,500.00 05/21/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/​Miglustat in IOPD Subjects Aged 0 to <18 (ROSSELLA) No dispute reported 06/30/2026 1252320283
Principal investigator 1 SANOFI US SERVICES INC. $11,441.25 05/16/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Fabry Disease Registry Protocol No dispute reported 06/30/2026 1226119104
Principal investigator 1 Amicus Therapeutics, Inc. $39,000.00 05/14/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/​Miglustat in IOPD Subjects Aged 0 to <18 (ROSSELLA) No dispute reported 06/30/2026 1252320051
Principal investigator 1 SANOFI US SERVICES INC. $202.50 05/09/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Gaucher Disease Registry Protocol No dispute reported 06/30/2026 1226119100
Principal investigator 1 GENZYME CORPORATION $59,269.00 04/14/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
An Open-label, Multinational, Multicenter, Intravenous Infusion Study of the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Avalglucosidase Alfa in Treatment naive Pediatric Participants With Infantile-Onset Pompe Disease (IOPD) No dispute reported 06/30/2026 1226123389
Principal investigator 1 GENZYME CORPORATION $21,712.00 04/07/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
An Open-label, Multinational, Multicenter, Intravenous Infusion Study of the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Avalglucosidase Alfa in Treatment naive Pediatric Participants With Infantile-Onset Pompe Disease (IOPD) No dispute reported 06/30/2026 1226123367
Principal investigator 1 Amicus Therapeutics, Inc. $318.46 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252319853
Principal investigator 1 Amicus Therapeutics, Inc. $796.23 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252319855
Principal investigator 1 Amicus Therapeutics, Inc. $75.20 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252319861
Principal investigator 1 Amicus Therapeutics, Inc. $75.20 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252319863
Principal investigator 1 Amicus Therapeutics, Inc. $796.23 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252319865
Principal investigator 1 Amicus Therapeutics, Inc. $318.46 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252319867
Principal investigator 1 Amicus Therapeutics, Inc. $318.46 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252319869
Principal investigator 1 Amicus Therapeutics, Inc. $207.09 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252319871
Principal investigator 1 Amicus Therapeutics, Inc. $318.46 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252319873
Principal investigator 1 Amicus Therapeutics, Inc. $318.46 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252319875
Principal investigator 1 Amicus Therapeutics, Inc. $75.20 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252319877
Principal investigator 1 Amicus Therapeutics, Inc. $207.09 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252319879
Principal investigator 1 Amicus Therapeutics, Inc. $75.20 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252319971
Principal investigator 1 Amicus Therapeutics, Inc. $75.20 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252319977
Principal investigator 1 Amicus Therapeutics, Inc. $75.20 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252319979
Principal investigator 1 Amicus Therapeutics, Inc. $75.20 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252319981
Principal investigator 1 Amicus Therapeutics, Inc. $846.86 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252319983
Principal investigator 1 Amicus Therapeutics, Inc. $207.09 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252319985
Principal investigator 1 Amicus Therapeutics, Inc. $802.98 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252319987
Principal investigator 1 Amicus Therapeutics, Inc. $318.46 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252319989
Principal investigator 1 Amicus Therapeutics, Inc. $75.20 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252319991
Principal investigator 1 Amicus Therapeutics, Inc. $207.09 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252319993
Principal investigator 1 Amicus Therapeutics, Inc. $75.20 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320079
Principal investigator 1 Amicus Therapeutics, Inc. $93.15 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320091
Principal investigator 1 Amicus Therapeutics, Inc. $75.20 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320093
Principal investigator 1 Amicus Therapeutics, Inc. $75.20 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320095
Principal investigator 1 Amicus Therapeutics, Inc. $75.20 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320097
Principal investigator 1 Amicus Therapeutics, Inc. $75.20 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320099
Principal investigator 1 Amicus Therapeutics, Inc. $75.20 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320101
Principal investigator 1 Amicus Therapeutics, Inc. $75.20 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320103
Principal investigator 1 Amicus Therapeutics, Inc. $75.20 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320105
Principal investigator 1 Amicus Therapeutics, Inc. $75.20 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320107
Principal investigator 1 Amicus Therapeutics, Inc. $75.20 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320109
Principal investigator 1 Amicus Therapeutics, Inc. $75.20 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320111
Principal investigator 1 Amicus Therapeutics, Inc. $318.46 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320187
Principal investigator 1 Amicus Therapeutics, Inc. $796.23 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320201
Principal investigator 1 Amicus Therapeutics, Inc. $207.09 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320207
Principal investigator 1 Amicus Therapeutics, Inc. $75.20 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320209
Principal investigator 1 Amicus Therapeutics, Inc. $846.86 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320211
Principal investigator 1 Amicus Therapeutics, Inc. $75.20 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320213
Principal investigator 1 Amicus Therapeutics, Inc. $75.20 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320215
Principal investigator 1 Amicus Therapeutics, Inc. $75.20 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320217
Principal investigator 1 Amicus Therapeutics, Inc. $207.09 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320219
Principal investigator 1 Amicus Therapeutics, Inc. $802.98 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320221
Principal investigator 1 Amicus Therapeutics, Inc. $796.23 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320223
Principal investigator 1 Amicus Therapeutics, Inc. $207.09 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320225
Principal investigator 1 Amicus Therapeutics, Inc. $3,300.00 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320227
Principal investigator 1 Amicus Therapeutics, Inc. $207.09 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320229
Principal investigator 1 Amicus Therapeutics, Inc. $802.98 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320309
Principal investigator 1 Amicus Therapeutics, Inc. $207.09 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320311
Principal investigator 1 Amicus Therapeutics, Inc. $75.20 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320313
Principal investigator 1 Amicus Therapeutics, Inc. $207.09 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320315
Principal investigator 1 Amicus Therapeutics, Inc. $207.09 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320319
Principal investigator 1 Amicus Therapeutics, Inc. $75.20 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320321
Principal investigator 1 Amicus Therapeutics, Inc. $318.46 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320325
Principal investigator 1 Amicus Therapeutics, Inc. $93.15 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320327
Principal investigator 1 Amicus Therapeutics, Inc. $207.09 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320379
Principal investigator 1 Amicus Therapeutics, Inc. $207.09 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320381
Principal investigator 1 Amicus Therapeutics, Inc. $846.86 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320385
Principal investigator 1 Amicus Therapeutics, Inc. $75.20 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320387
Principal investigator 1 Amicus Therapeutics, Inc. $75.20 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320389
Principal investigator 1 Amicus Therapeutics, Inc. $75.20 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320391
Principal investigator 1 Amicus Therapeutics, Inc. $796.23 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320393
Principal investigator 1 Amicus Therapeutics, Inc. $75.20 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320395
Principal investigator 1 Amicus Therapeutics, Inc. $75.20 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320397
Principal investigator 1 Amicus Therapeutics, Inc. $8,000.00 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320399
Principal investigator 1 Amicus Therapeutics, Inc. $2,000.00 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320401
Principal investigator 1 Amicus Therapeutics, Inc. $207.09 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320475
Principal investigator 1 Amicus Therapeutics, Inc. $802.98 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320477
Principal investigator 1 Amicus Therapeutics, Inc. $93.15 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320485
Principal investigator 1 Amicus Therapeutics, Inc. $318.46 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320493
Principal investigator 1 Amicus Therapeutics, Inc. $93.15 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320495
Principal investigator 1 Amicus Therapeutics, Inc. $75.20 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320497
Principal investigator 1 Amicus Therapeutics, Inc. $207.09 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320499
Principal investigator 1 Amicus Therapeutics, Inc. $846.86 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320501
Principal investigator 1 Amicus Therapeutics, Inc. $75.20 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320503
Principal investigator 1 Amicus Therapeutics, Inc. $75.20 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320505
Principal investigator 1 Amicus Therapeutics, Inc. $207.09 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320507
Principal investigator 1 Amicus Therapeutics, Inc. $838.35 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320581
Principal investigator 1 Amicus Therapeutics, Inc. $802.98 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320583
Principal investigator 1 Amicus Therapeutics, Inc. $846.86 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320585
Principal investigator 1 Amicus Therapeutics, Inc. $75.20 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320587
Principal investigator 1 Amicus Therapeutics, Inc. $207.09 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320591
Principal investigator 1 Amicus Therapeutics, Inc. $75.20 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320593
Principal investigator 1 Amicus Therapeutics, Inc. $802.98 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320597
Principal investigator 1 Amicus Therapeutics, Inc. $207.09 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320599
Principal investigator 1 Amicus Therapeutics, Inc. $75.20 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320601
Principal investigator 1 Amicus Therapeutics, Inc. $75.20 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320603
Principal investigator 1 Amicus Therapeutics, Inc. $75.20 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320605
Principal investigator 1 Amicus Therapeutics, Inc. $93.15 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320607
Principal investigator 1 Amicus Therapeutics, Inc. $4,500.00 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320609
Principal investigator 1 Amicus Therapeutics, Inc. $6,000.00 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320611
Principal investigator 1 Amicus Therapeutics, Inc. $9,600.00 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320613
Principal investigator 1 Amicus Therapeutics, Inc. $75.20 04/03/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease No dispute reported 06/30/2026 1252320615
Principal investigator 1 GENZYME CORPORATION $33,474.00 03/17/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
An Open-label, Multinational, Multicenter, Intravenous Infusion Study of the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Avalglucosidase Alfa in Treatment naive Pediatric Participants With Infantile-Onset Pompe Disease (IOPD) No dispute reported 06/30/2026 1226123363
Principal investigator 1 GENZYME CORPORATION $3,500.00 03/04/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
A Randomized, Double-blind, Placebo-controlled, 12-month Phase 3 Study to Evaluate the Effect of Venglustat on Neuropathic and Abdominal Pain in Male and Female Adults With Fabry Disease Who Are Treatment-naive or Untreated for at Least 6 Months No dispute reported 06/30/2026 1226119030
Principal investigator 1 SANOFI US SERVICES INC. $8,268.75 02/19/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Gaucher Disease Registry Protocol No dispute reported 06/30/2026 1226093162
Principal investigator 1 SANOFI US SERVICES INC. $3,847.50 02/12/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Fabry Disease Registry Protocol No dispute reported 06/30/2026 1226093150
Principal investigator 1 GENZYME CORPORATION $4,910.00 02/10/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
A Randomized, Double-blind, Placebo-controlled, 12-month Phase 3 Study to Evaluate the Effect of Venglustat on Neuropathic and Abdominal Pain in Male and Female Adults With Fabry Disease Who Are Treatment-naive or Untreated for at Least 6 Months No dispute reported 06/30/2026 1226119027
Principal investigator 1 GENZYME CORPORATION $56,318.00 02/10/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
An Open-label, Multinational, Multicenter, Intravenous Infusion Study of the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Avalglucosidase Alfa in Treatment naive Pediatric Participants With Infantile-Onset Pompe Disease (IOPD) No dispute reported 06/30/2026 1226123356
Principal investigator 1 GENZYME CORPORATION $4,000.00 02/10/2025 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
An Open-label, Multinational, Multicenter, Intravenous Infusion Study of the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Avalglucosidase Alfa in Treatment naive Pediatric Participants With Infantile-Onset Pompe Disease (IOPD) No dispute reported 06/30/2026 1226123359